Sign In

Also in this Section

Media Contact:

Nola Gruneisen
Phone: 571-292-3068
Email: media@aasld.org

Five Years of Regular Aspirin Use Helps Prevent Common Liver Cancer

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that taking a regular aspirin is associated with a dose-dependent reduction in the risk of hepatocellular carcinoma, one of the most common liver cancers.

Read the press release.

Weight-Loss Surgery Effectively Reduces Weight and Lowers Risk of Post- Liver Transplant Complications in Obese Patients

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that weight-loss surgery prior to liver transplantation is superior to medical weight loss approaches at achieving sustained weight loss, as well as significantly lowering risk of metabolic complications after transplant.

Read the press release.

Clinically Significant Liver Toxicity Related to Anti-Cancer Drugs is Rare but Often Leads to Discontinuation of Treatment

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that patients treated with immune checkpoint inhibitors rarely develop severe liver toxicity, but the majority of those who do permanently stop this cancer treatment. None of the patients developed liver failure as a result of this treatment.

Read the press release.

Liver Cancer Combined with Other Liver Diseases Driving Higher Death Rate and Health Care Costs for US Seniors

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that hospitalizations and death are increasing among Medicare recipients with hepatocellular carcinoma, mainly due to co-existing alcoholic liver disease, hepatitis C virus infection (commonly called HCV) and nonalcoholic fatty liver disease (commonly called NAFLD).

Read the press release.

People with Hepatitis C Who Actively Inject Illegal Drugs Have High Rates of Hepatitis C Treatment Adherence and Cure

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that people who inject drugs who are infected with the hepatitis C virus have high rates of hepatitis C treatment adherence (completion of their treatment), and sustained virologic response.

Read the press release.

African-Americans Face Significant Delays in Liver Transplantation Despite High Priority Scores

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that African-American patients on waitlists for liver transplantation, despite severe disease and high scores for prioritization, persistently face significant disparities and delays in referral.

Read the press release.

Combined Glecaprevir and Pibrentasvir Found Highly Effective in Chronic Hepatitis C Patients Who Have Failed Other Therapies

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found the combination of glecaprevir and pibrentasvir is highly effective and well tolerated in patients with chronic hepatitis C virus (commonly called HCV) genotype-1 infections who have prior treatment experience with sofosbuvir/NS5A inhibitor.

Read the press release.

Universal Hepatitis C Screening of Pregnant Women More Cost-Effective Than Risk-Based Approach

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that universal screening of pregnant women at risk for hepatitis C virus (commonly called HCV) infection is a more efficient and cost-effective diagnostic approach than risk-based screening.

Read the press release.

Nonalcoholic Fatty Liver Disease Patients Have Higher Rates of All Non-Liver-Related Cancers

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that rates of malignancy occurring outside of the liver were higher in adults with nonalcoholic fatty liver disease than among adults across most types of cancers.

Read the press release.

Normothermic Machine Perfusion Can Salvage Fatty Livers for Transplantation

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that using normothermic machine perfusion to preserve steatotic livers leads to altered lipid structure and metabolism and may result in more successful transplantation of these organs.

Read the press release.

Preemptive Antiviral Therapy Prevents Chronic Hepatitis C Infection in Heart Transplant Patients Who Receive Infected Donor Organs

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.

Read the press release.

Under-Immunization Still a Major Problem in Pediatric Liver Transplant Patient Population

November 9, 2018
Data from a new study presented this week at The Liver Meeting® found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk for vaccine-preventable infections.

Read the press release.

Can You Inherit a Fatty Liver?

October 20, 2017
Serum metabolites associated with nonalcoholic fatty liver disease may be heritable, according to research presented this week at The Liver Meeting®.

http://www.aasld.org/about-aasld/press-room/can-you-inherit-fatty-liver

Cardiovascular Risk in Women with Fatty Liver Disease: Risk is Not Equal Opportunity

October 20, 2017
Nonalcoholic fatty liver disease is associated with significantly higher risk of subsequent cardiovascular events in women, but not in men, according to research presented this week at The Liver Meeting®.

http://www.aasld.org/about-aasld/press-room/cardiovascular-risk-women-fatty-liver-disease-risk-not-equal-opportunity

Deaths Rates of Liver Cirrhosis Exceed Those of 5 Major Cancers

October 20, 2017
A new study presented this week at The Liver Meeting® found that liver cirrhosis mortality is greater than that of five major cancers, implying the development of appropriate interventions to treat or prevent liver cirrhosis must be prioritized.

http://www.aasld.org/about-aasld/press-room/deaths-rates-liver-cirrhosis-exceed-those-5-major-cancers

Direct‐Acting Antiviral Therapy Cuts Liver Cancer Risk By 71%

October 20, 2017
A new study presented this week at The Liver Meeting® found that eradication of the hepatitis C virus induced by direct‐acting antiviral medications is associated with a 71 percent reduction in the risk of liver cancer.

http://www.aasld.org/about-aasld/press-room/direct%E2%80%90acting-antiviral-therapy-cuts-liver-cancer-risk-71

One Liver. Two Saved Lives.

October 20, 2017
A new study presented this week at The Liver Meeting® found that increased utilization of split liver transplantation (sharing a donor liver between one pediatric and one adult patient) could decrease the number of children who die awaiting liver transplantation without decreasing liver transplantation access for adult patients.

http://www.aasld.org/about-aasld/press-room/one-liver-two-saved-lives

Pregnancy Rates on the Rise Among Women with Chronic Liver Disease

October 20, 2017
A new study presented this week at The Liver Meeting® found that the overall number of pregnancies in women with chronic liver disease or following liver transplantation has risen over the past 30 years. In addition, the proportion of full‐term pregnancies has increased significantly over that time period, and most women had favorable pregnancy outcomes.

http://www.aasld.org/about-aasld/press-room/pregnancy-rates-rise-among-women-chronic-liver-disease

November 14, 2018
Hepatitis C is a viral illness that affects the liver. Men tend to experience it at higher rates than women, but it is unclear why. Some people believe that it may be due to estrogen’s protective effect. Diagnosis and testing can help people find treatment. Learn more about hepatitis C in men here.
November 14, 2018
Hepatitis C is a viral infection that can cause substantial liver damage, particularly in the later stages. The treatment and outlook will depend on the progression of the disease. Learn more here.
November 2, 2018

For the past 22 years, at this point in the year, we would be talking about how to get the government funded and off a Continuing Resolution. This year, however, for the first time since 1996, funding for the discretionary programs SGIM members care most about – NIH, CDC, AHRQ, VA research – have all been passed by the Congress and signed into law by the President.

November 2, 2018

Because The Liver Meeting® remains the most important event in the liver year, I would like to take this opportunity to walk you through some of the meeting highlights.